Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Luminespib - Vernalis

Drug Profile

Luminespib - Vernalis

Alternative Names: AUY-922; NVP-AUY-922; VER-52296

Latest Information Update: 02 Oct 2021

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Cancer Research Technology; The Institute of Cancer Research; Vernalis
  • Developer Memorial Sloan-Kettering Cancer Center; Novartis; Sarah Cannon Research Institute; SCRI Development Innovations; University of Texas M. D. Anderson Cancer Center; University of Toronto; Vernalis
  • Class Amides; Antineoplastics; Isoxazoles; Morpholines; Resorcinols; Small molecules
  • Mechanism of Action HSP90 heat-shock protein inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

  • New Molecular Entity Yes
  • Available For Licensing Yes - COVID 2019 infections

Highest Development Phases

  • Discontinued Colorectal cancer; Gastric cancer; Gastrointestinal stromal tumours; HER2 positive breast cancer; Lymphoma; Multiple myeloma; Myeloproliferative disorders; Non-small cell lung cancer; Pancreatic cancer; Solid tumours

Most Recent Events

  • 13 Apr 2020 Luminespib - Vernalis is available for licensing as of 13 Apr 2020. https://www.vernalis.com/
  • 13 Apr 2020 Discontinued - Phase-I for Colorectal cancer (Combination therapy, Second-line therapy or greater) in USA (IV)
  • 13 Apr 2020 Discontinued - Phase-I for Gastric cancer (Combination therapy, Late-stage disease, Second-line therapy or greater) in USA, Germany, South Korea, Switzerland, Taiwan (IV)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with username/password or try via your institution
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top